Assessment of cardiac inflammation and remodeling during the development of streptozotocin-induced diabetic cardiomyopathy in vivo: A time course analysis

International Journal of Molecular Medicine

Volumn 32, Issue 1, 2013, Pages 158-164

  Becher, P M ^a   Lindner, D ^a   Frohlich M ^a   Savvatis, K ^a   Westermann, D ^a   Tschöpe, Carsten ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Cardiac function; Diabetic cardiomyopathy; Inflammation; Remodeling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; GELATINASE A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDITIS; CELL INFILTRATION; CELL INVASION; CELLULAR IMMUNITY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART OUTPUT; IMMUNE RESPONSE; IMMUNOHISTOLOGY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; STRESS;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; EXTRACELLULAR MATRIX; FIBROSIS; HEMODYNAMICS; INFLAMMATION; OXIDATIVE STRESS; RATS; STREPTOZOCIN; TIME FACTORS; VENTRICULAR REMODELING;

EID: 84878261370     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2013.1368     Document Type: Article

References (31)

1. Poornima IG, Parikh P and Shannon RP: Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98: 596-605, 2006.
2. Grundy SM, Benjamin IJ, Burke GL, et al: Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134-1146, 1999. (Pubitemid 29416243)
3. Howard BV and Wylie-Rosett J: Sugar and cardiovascular disease: a statement for healthcare professionals from the Committee on Nutrition of the Council on Nutrition, Physical Activity, and Metabolism of the American Heart Association. Circulation 106: 523-527, 2002. (Pubitemid 34803702)
4. Devereux RB, Roman MJ, Paranicas M, et al: Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101: 2271-2276, 2000. (Pubitemid 30317129)
5. Cai L, Li W, Wang G, Guo L, Jiang Y and Kang YJ: Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51: 1938-1948, 2002. (Pubitemid 34564309)
6. Heymans S, Hirsch E, Anker SD, et al: Inflammation as a therapeutic target in heart failure? a scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11: 119-129, 2009.
7. Tschope C, Walther T, Koniger J, et al: Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. FASEB J 18: 828-835, 2004. (Pubitemid 38544501)
8. + transport in diabetic heart of transgenic rats expressing the human kallikrein-1 gene. FASEB J 18: 1967-1969, 2004.
9. Westermann D, Rutschow S, Jager S, et al: Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56: 641-646, 2007. (Pubitemid 46348458)
10. Riad A, Westermann D, Van Linthout S, et al: Enhancement of endothelial nitric oxide synthase production reverses vascular dysfunction and inflammation in the hindlimbs of a rat model of diabetes. Diabetologia 51: 2325-2332, 2008.
11. Westermann D, Van Linthout S, Dhayat S, et al: Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 56: 1834-1841, 2007. (Pubitemid 47025453)
12. Westermann D, Rutschow S, Van Linthout S, et al: Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus. Diabetologia 49: 2507-2513, 2006. (Pubitemid 44359113)
13. Westermann D, Becher PM, Lindner D, et al: Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunc tion, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol 107: 308, 2012.
14. Becher PM, Lindner D, Miteva K, et al: Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and beta-receptor blockade. Hypertension 59: 949-957, 2012.
15. Wang J, Song Y, Elsherif L, et al: Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 113: 544-554, 2006.
16. Westermann D, Van Linthout S, Dhayat S, et al: Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 102: 500-507, 2007. (Pubitemid 47578394)
17. Van Linthout S, Riad A, Dhayat N, et al: Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia 50: 1977-1986, 2007. (Pubitemid 47222844)
18. Dorenkamp M, Riad A, Stiehl S, et al: Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism. Eur J Pharmacol 520: 179-187, 2005. (Pubitemid 41375827)
19. Savvatis K, Westermann D, Schultheiss HP and Tschope C: Kinins in cardiac inflammation and regeneration: insights from ischemic and diabetic cardiomyopathy. Neuropeptides 44: 119-125, 2010.
20. Yeghiazaryan K, Bauriedel G, Schild HH and Golubnitschaja O: Prediction of degeneration of native and bioprosthetic aortic valves: issue-related particularities of diabetes mellitus. Infect Disord Drug Targets 8: 88-99, 2008. (Pubitemid 351936178)
21. Marwick TH: Diabetic heart disease. Heart 92: 296-300, 2006.
22. Tyagi SC and Hayden MR: Role of nitric oxide in matrix remodeling in diabetes and heart failure. Heart Fail Rev 8: 23-28, 2003. (Pubitemid 36342287)
23. Tsioufis C, Bafakis I, Kasiakogias A and Stefanadis C: The role of matrix metalloproteinases in diabetes mellitus. Curr Top Med Chem 2: 1159-1165, 2012.
24. Leask A: Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106: 1675-1680, 2010.
25. Hammoud L, Lu X, Lei M and Feng Q: Deficiency in TIMP-3 increases cardiac rupture and mortality post-myocardial infarc tion via EGFR signaling: beneficial effects of cetuximab. Basic Res Cardiol 106: 459-471, 2011.
26. Bugger H and Abel ED: Mitochondria in the diabetic heart. Cardiovasc Res 88: 229-240, 2010.
27. Henderson BC and Tyagi SC: Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure. J Mol Cell Cardiol 41: 959-962, 2006. (Pubitemid 44791336)
28. La Rocca G, Di Stefano A, Eleuteri E, et al: Oxidative stress induces myeloperoxidase expression in endocardial endothe lial cells from patients with chronic heart failure. Basic Res Cardiol 104: 307-320, 2009.
29. Regan TJ, Wu CF, Yeh CK, Oldewurtel HA and Haider B: Myocardial composition and function in diabetes. The effects of chronic insulin use. Circ Res 49: 1268-1277, 1981. (Pubitemid 12246596)
30. Iribarren C, Karter AJ, Go AS, et al: Glycemic control and heart failure among adult patients with diabetes. Circulation 103: 2668-2673, 2001. (Pubitemid 32538780)
31. Dhalla NS, Pierce GN, Innes IR and Beamish RE: Pathogenesis of cardiac dysfunction in diabetes mellitus. Can J Cardiol 1: 263-281, 1985. (Pubitemid 15236913)